Jeong Dajeong, Oh Sujin, Song Eun Young, Hong Yun Ji, Park Kyoung Un
Department of Laboratory Medicine, Seoul National University College of Medicine, Seoul 03080, Korea.
Department of Laboratory Medicine, Seoul National University Bundang Hospital, Seongnam 13620, Korea.
Diagnostics (Basel). 2021 May 21;11(6):920. doi: 10.3390/diagnostics11060920.
Serological weak D is a reaction of 2+ or less to anti-D reagent and includes weak D and partial D phenotypes. Although identifying the RhD subtype is important for transfusion safety, serological tests are insufficient for defining the RhD subtype, and molecular tests are needed. To analyze the molecular characteristics of D variants in Koreans to facilitate the formulation of individualized transfusion strategies, molecular tests such as RhD genotyping using real-time polymerase chain reaction (PCR) and partial-D and/or weak-D sequence-specific amplification (SSP) were performed on 105 Korean Rare Blood Program (KRBP) patients exhibiting serological weak D. In total, 58 out of 68 serologically determined weak D KRBP patients were typed as having weak D or partial D phenotypes via RhD genotyping. In detail, eight (13.8%) were typed as partial DVa or DBS, nine (15.5%) as weak D type 15, and four others (6.8%) as partial DVI, partial DVII, weak D type 2, or weak D type 41 or 45, whereas the rest (n = 37, 63.8%) was typed as having either weak D or partial D. This suggests that serological weak D Koreans who require transfusion should be treated as D-negative.
血清学弱 D 是指与抗 - D 试剂反应为 2 + 或更低的反应,包括弱 D 和部分 D 表型。尽管确定 RhD 亚型对输血安全很重要,但血清学检测不足以定义 RhD 亚型,需要进行分子检测。为了分析韩国人 D 变异体的分子特征以促进个体化输血策略的制定,对 105 名表现出血清学弱 D 的韩国稀有血型计划(KRBP)患者进行了分子检测,如使用实时聚合酶链反应(PCR)进行 RhD 基因分型以及部分 D 和/或弱 D 序列特异性扩增(SSP)。总共,68 名血清学检测确定为弱 D 的 KRBP 患者中,有 58 名通过 RhD 基因分型被确定为具有弱 D 或部分 D 表型。详细来说,8 名(13.8%)被确定为部分 DVa 或 DBS,9 名(15.5%)为弱 D 型 15,另外 4 名(6.8%)为部分 DVI、部分 DVII、弱 D 型 2 或弱 D 型 41 或 45,而其余(n = 37,63.8%)被确定为具有弱 D 或部分 D。这表明需要输血的血清学弱 D 韩国人应被视为 D 阴性。